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Introduction: Diabetes mellitus is a significant risk factor for atherosclerotic peripheral vascular disease. Hyperglycemia
and hyperinsulinemia, as encountered in patients with type II diabetes, have been shown to stimulate vascular smooth
muscle cell (VSMC) proliferation, a paramount feature in atherosclerosis. Female sex hormones, such as estrogen, have
been suggested to inhibit VSMC proliferation. However, the role of progesterone, particularly in patients with diabetes
mellitus, has not been examined. Therefore, we studied the effect of progesterone on VSMCs exposed to various
concentrations of glucose and insulin.
Methods: Human infragenicular VSMCs isolated from the tibial arteries of five male patients with diabetes undergoing
lower extremity amputation were used. Immunocytochemical studies with confocal microscopy were performed for
progesterone receptor identification in these VSMCs. Cells were grown to subconfluence, followed by exposure to
deprived media with various glucose (100 and 200 mg/dL) and insulin (no insulin and 100 ng/mL) concentrations.
Cells were then additionally exposed to physiologic progesterone (10 ng/mL, progesterone group) and compared with
a no-progesterone group. Cell count and methyl-3H–thymidine incorporation were used to determine cellular prolifer-
ation. Cell count with hemocytometry was performed on day 6. DNA synthesis as reflected through methyl-3H–
thymidine incorporation was measured at 24 hours.
Results: Immunocytochemical studies with confocal microscopy showed cytosolic progesterone receptors. The no-
progesterone group showed a significant rise in cell count (P < .05) at all concentrations of glucose or insulin compared
with the control group containing 100 mg/dL glucose concentration. The no-progesterone group also showed a
significant rise in thymidine incorporation (P < .05) in the 100 mg/dL glucose–100 ng/mL insulin group and the 200
mg/dL glucose–100 ng/mL insulin group compared with the 100 mg/dL glucose group. In the cell count studies,
progesterone significantly inhibited cellular proliferation in several settings. All cell groups cultured with insulin or an
elevated glucose concentration showed a significant (P < .05) antiproliferative effect when exposed to progesterone. With
thymidine incorporation, progesterone showed a similar antiproliferative effect in cells stimulated with glucose or insulin.
Conclusion: Significant reductions in cell proliferation as determined with both cell count and thymidine incorporation
suggest that progesterone is an inhibitor of VSMC proliferation induced by our in vitro models of hyperglycemia and
hyperinsulinemia. Therefore, progesterone may have a protective role against the atherosclerotic changes associated with
type II diabetes. (J Vasc Surg 2002;36:833-8.)
Diabetes mellitus (DM) continues to remain a chal-
lenging medical problem in the United States. DM affects
6.6% of the adult population1 and has been identified as an
independent risk factor for atherosclerosis.2 Impaired glu-
cose tolerance (IGT), a prediabetic stage, is also associated
with accelerated atherosclerosis.3 Peripheral vascular dis-
ease involving the infragenicular vessels is common in DM
and may result in limb-threatening ischemia. Type 2 DM is
the most common form of the disease4 and is characterized
by insulin receptor resistance or dysfunction resulting in
hyperinsulinemia and hyperglycemia. Vascular smooth
muscle cell (VSMC) proliferation and migration is an im-
portant part of the atherosclerotic process and occurs as an
early event in plaque formation.5,6 Enhanced proliferation
of VSMCs resulting from elevated glucose and insulin
concentrations has been observed in the in vitro setting,7
which may in part explain the acceleration of the athero-
sclerotic process in patients with type 2 DM or IGT.
In general, the incidence rate of cardiovascular compli-
cations in premenopausal women is lower than that in
men,8 but after menopause, the mortality and morbidity
rates approximate those of age-matched men.9 The cardio-
protective effects of estrogen are well recognized; post-
menopausal women given estrogen replacement therapy
have a lower incidence rate of cardiovascular events (non-
fatal myocardial infarction or fatal coronary disease) than
do untreated patients.10
Possible mechanisms for this cardioprotective effect
include alterations in lipid profiles (decreased low density
lipoprotein and increased high density lipoprotein choles-
terol levels),11 improved endothelial function,12 and re-
duced proliferation of VSMCs.13 Estrogen and progester-
one have been shown to inhibit the proliferation and
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migration of VSMC in cultures obtained from both male
and female specimens11,14,15; however, the role of proges-
terone in the setting of diabetic vascular disease is un-
known. Therefore, we examined human infragenicular
VSMCs from patients with diabetes to determine whether
they contained progesterone receptors and evaluated the
effects of progesterone on the proliferation of infragenicu-
lar VSMCs in response to various concentrations of glucose
and insulin.
MATERIALS AND METHODS
Harvesting and cell characterization
The protocol and informed consent form both had
prior approval by the Institutional Review Board, and all
subjects gave informed consent. Segments of human tibial
arteries were obtained at the time of lower extremity am-
putation performed on five male patients with diabetes with
end-stage peripheral vascular disease. The mean age of the
patients was 70.8 years (4.26 years, standard deviation).
After excision of the vessels from the amputation specimen,
the media were immediately dissected from the other vessel
layers, minced, and incubated in a 0.8% collagenase and
0.05% elastase solution for 2 to 4 hours. The cells were
centrifuged, rinsed, and immersed in a solution containing
Medium-199 (Gibco BRL, Grand Island, NY), 10% fetal
bovine serum (Gibco BRL), and 2% antibiotic-antimycotic
(AA; 10,000 U/mL penicillin G sodium, 10,000 g/mL
streptomycin sulfate, and 25 g/mL amphotericin B;
Gibco BRL). Cells in solution were transferred to 75-cm2
vented culture flasks and incubated at 37° C in a humidified
incubator at 5% CO2. When the cultures reached subcon-
fluence, cells were trypsinized with 0.25% trypsin–ethyl-
enediamine tetraacetic acid (Gibco BRL) and subcultured.
This experiment used cells from passages 2 to 5, and cells
were combined into a single mixed culture before transfer
to wells at the beginning of this study.
Cells were identified as smooth muscle cells at first
passage with a previously described immunohistochemistry
technique.16 Briefly, the cells were plated in culture cham-
bers at 35,000 cells/mL, allowed to grow to subconflu-
ence, and incubated overnight with primary antibodies
directed against -smooth muscle actin, myosin, vimentin,
desmin, vitronectin, chondroitin sulfate, and fibronectin.
Fluorescein-tagged secondary antibodies were added to the
culture chambers, and cells were subsequently identified
with fluorescent light microscopy.
Progesterone receptor detection
Confocal laser-scanning immunofluorescence micros-
copy was used to detect the presence of progesterone
receptors in VSMCs. VSMCs were plated onto double-
chambered slides (LabTek II, Nalge Nunc International,
Naperville, Ill) previously coated with laminin (Sigma, St
Louis, Mo). This was done at a density of 15,000 cells/mL
per well. These cells were allowed 48 hours for adherence.
They then were fixed with 1% formalin in phosphate buff-
ered saline solution (PBS; Gibco BRL) followed by 1%
formalin with 0.02% Triton X-100. Nonspecific binding
was blocked with 10% normal goat serum in PBS. The slides
then were washed with PBS and probed overnight at 4° C
with rabbit polyclonal progesterone receptor antibody (sc-
538, SCBT, Santa Cruz, Calif) in a 1:80 dilution. Control
slides were prepared with the omission of the primary
antibody. After washing with PBS, the slides then were
probed with rhodamine conjugated goat anti-rabbit sec-
ondary antibody (Jackson ImmunoResearch, West Grove,
Pa). This was diluted to 1:1000 in 1.5% normal goat serum
and PBS and placed in a humidified chamber for 1 hour.
After washing, a coverslip was placed over the slide with a
drop of fluorescent compatible mounting media (Sigma)
and sealed with clear nail polish. The slides then were
examined with an inverted confocal laser-scanning micro-
scope (Nikon, Inc, Melville, NY). A Radiance 2000 laser
scanning system (Bio-Rad Microscopy Div, Hertfordshire,
United Kingdom) was the source for the argon/krypton
laser beam. Samples were imaged with a broad bandpass
emission filter with excitation at 568 nm with 60 oil
immersion and 20 objectives. Digital images were ana-
lyzed with MetaMorph (Universal Imaging, West Chester,
Pa), and figures were prepared with Adobe Photoshop
(Adobe Systems, Mountain View, Calif).
Proliferation studies
The VSMCs were pooled into a mixed culture, grown
to subconfluence, and divided into various groups to exam-
ine the effects of progesterone (Sigma) on the proliferation
of VSMCs exposed to various concentrations of glucose
and insulin (Fig 1). The first group, the no-progesterone
group, was exposed to deprived media (M-199, 2% AA)
without progesterone. This group consisted of the follow-
ing glucose (Sigma) and insulin (bovine pancreas, Sigma)
concentrations: 100 mg/dL glucose (control), 100
mg/dL glucose–100 ng/mL insulin (100glu-100ins), 200
mg/dL glucose (200glu), and 200 mg/dL glucose–100
ng/mL insulin (200glu-100ins). The second group of
cells, the progesterone group, was likewise cultured in the
same glucose and insulin concentrations with the addition
of 10 ng/mL progesterone. Arterial smooth muscle prolif-
eration was assessed with two different methods: cell count
and methyl-3H–thymidine incorporation.
Fig 1. Flow diagram shows study design. Glucose concentration
in mg/dL, insulin concentration in ng/mL, and progesterone
concentration in ng/mL. *Control group.
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Cell count. Cells were seeded in six-well plates at
10,000 cells/mL in 2 mL of fortified media (M-199, 10%
fetal bovine serum, 2% AA) and allowed 48 hours for
attachment. They were subsequently incubated in deprived
media for an additional 48 hours to achieve quiescence.
The various groups of VSMCs were exposed to the differ-
ent concentrations of glucose, insulin, and progesterone
described (Fig 1). Cells were counted in triplicate with
standard hemocytometry on day 6.6 Culture medium, in-
cluding glucose, insulin, and progesterone, was replaced on
days 2 and 4. Values were expressed as the mean  the
standard error of the mean from six wells from each group
(total of 18 experiments per group).
Thymidine incorporation. VSMCs were placed in
24-well plates at 30,000 cells/well in 1 mL of fortified
medium and allowed to grow to subconfluence. Cells
were exposed to deprived medium for an additional 48
hours to make them quiescent. The various concentra-
tions of glucose, insulin, and progesterone were added as
described (Fig 1). VSMCs were incubated at 37° C in
these conditions for 20 hours, at which point methyl-
3H–thymidine (2 Ci/well; Amersham Pharmacia Bio-
tech, Piscataway, NJ) was added. At 24 hours, VSMCs
were rinsed three times with PBS. The incorporated
methyl-3H–thymidine was extracted with 0.2N NaOH
and precipitated with 10% trichloroacetic acid before
quantification in a Beckman LS6500 liquid scintillation
counter (Beckman, Fullerton, Calif). Values were mea-
sured as decays per minute (DPM) and then expressed as
the mean percentage the standard error of the mean as
compared with controls from 12 wells.
Statistical analysis
Statistical analysis was performed with Sigmastat soft-
ware (Jandel Scientific Software, San Rafael, Calif). One-
way analysis of variance was used to compare the results of
the cell count and thymidine incorporation of various glu-
cose, insulin, and progesterone groups. Statistical signifi-
cance was identified as P less than .05.
RESULTS
Cell characterization. VSMCs showed characteristic
cytoskeletal proteins by exhibiting strong fluorescence of
secondary antibodies when primary antibodies against
-smooth muscle actin, vimentin, fibronectin, and chon-
droitin sulfate were present. A weak fluorescence pattern
resulted when primary antibodies against desmin and vitro-
nectin were present. Cells incubated in the absence of
primary antibodies showed no specific fluorescence.
Progesterone receptor detection. When subjected to
confocal microscopy after labeling with a fluorescent anti-
body conjugated to a rabbit polyclonal antibody to the
progesterone receptor, human VSMCs show progesterone
receptor binding in red to be present in the cytoplasm of
the male arterial smooth muscle cell (Fig 2, B). The control
slides, exposed to no primary antibody, showed no fluores-
cence (image not shown). With the transmission image (Fig
2, A) viewed, the nucleus was observed and no fluorescence
was present in its location (Fig 2, B).
Effects of glucose, insulin, and progesterone on cell
proliferation. In the no-progesterone group, the addition
of glucose and insulin to VSMCs synergistically increased
cell proliferation as compared with control when counted
Fig 2. A, 60Oil immersion objective transmission image of VSMC. B, 60Oil immersion objective with confocal
laser-scanning immunofluorescence microscopy. Cells fixed and incubated as described in Methods at dilution of 1:80
progesterone receptor antibody. Anti–progesterone receptor antibody was detected with rhodamine conjugated goat
anti-rabbit secondary antibody diluted 1:1000, causing progesterone receptor to appear red. White arrow points to
position of nucleus.
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on day 6 (Fig 3). These increases ranged from 12%, when
the 100glu-100ins group was compared with the control
group (12,109  480 versus 10,694  574; P  .05), to
47%, when the 200glu-100ins group was compared with
the control group (15,764  632 versus 10,694  574;
P  .05). When progesterone (10 ng/mL) was added, an
antiproliferative effect was observed (Fig 3). An inhibition
in cell proliferation occurred with significant decreases in
cell count observed in the following groups: 100glu-
100ins, 200glu, and 200glu-100ins. These decreases
ranged from 16% (13,819  445 versus 9722  455; P 
.05) in the 100glu-100ins group when progesterone was
added to 30% (15,764  632 versus 10,972  405; P 
.05) in the 200glu-100ins group when progesterone was
added.
Effects of glucose, insulin, and progesterone on
thymidine incorporation. Because of the wide variability
in methyl-3H–thymidine uptake depending on the degree
of cell density, groups were compared with the DPM values
obtained in the control group without progesterone and
expressed as percent change compared with control. Con-
trol DPMs were considered as 100. In the no-progesterone
group, VSMCs exposed to 100glu-100ins and VSMCs
exposed to 200glu-100ins showed a significant (P  .05)
rise in thymidine incorporation when compared with con-
trol. A significant decrease in thymidine incorporation was
shown in several groups when progesterone was added (Fig
4). This effect was maximal in the group incubated with
100glu-100ins with a 58% reduction in proliferation (144%
 5% versus 84%  4%; P  .05).
DISCUSSION
Estrogen and progesterone act through interaction
with cytosolic receptors with translocation of these ligand-
receptor complexes into the nucleus, where highly specific
binding occurs with promotor regions of specific genes,
thus altering gene expression.13-15,17-19 Estrogen has been
postulated to regulate protooncogene expression and other
steroid-responsive genes, such as c-fos and c-myc.14,19 This
finding suggests that these hormones may directly affect
arterial smooth muscle cell function in addition to any
indirect action that may also occur, such as endothelial
release of nitric oxide.
Several investigators have shown inhibition of VSMC
proliferation with estrogen in various physiologic and re-
placement concentrations.11,13,14,20,21 These studies used
cells from both human and animal coronary arteries and
saphenous veins. Estrogen suppressed proliferation and
migration in VSMCs taken from these tissues. However,
the role of progesterone is unclear. Moreover, no previous
studies have assessed the effect of progesterone on the
proliferation of VSMCs from tibial arteries exposed to
increased concentrations of glucose and insulin.
We found progesterone to be a consistent inhibitor of
VSMC proliferation induced by elevated glucose and insu-
lin concentrations. Therefore, the conclusion that a proges-
terone-mediated antiproliferative effect in cells stimulated
by elevated glucose and insulin levels may protect against
the accelerated atherosclerotic complications that occur in
patients with DM or IGT is reasonable.
Several possible mechanisms may explain the altered
proliferation of VSMCs exposed to female hormones. First,
progesterone and estrogen, through their respective recep-
tors, may modulate gene expression at a site downstream to
the proliferative cascade initiated by glucose and insulin.19
Second, sex hormones may alter growth factor–stimulated
pathways. Sahlin, Norstedt, and Eriksson22 showed that sex
steroids directly regulate the insulin-like growth factor I
Fig 3. Effects of progesterone on smooth muscle cell proliferation determined with hemocytometer cell count in cells
stimulated with various glucose/insulin combinations. *P  .05 compared with identical glucose/insulin concentra-
tion. #P  .05 compared with control group.
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receptor. We have identified the insulin-like growth factor I
receptor as the mediator of insulin’s mitogenic effects in
these cells,23 so this relationship between estrogen, proges-
terone, and hyperinsulinemia may explain the antiprolifera-
tive effects of these sex hormones. Third, diabetic or glu-
cose intolerant conditions may alter steroid receptor
quantity and activity.24
Few studies have documented the effects of progester-
one on VSMCs. Lee and colleagues15 observed inhibition
of VSMC proliferation and thymidine incorporation with
physiologic and pharmacologic concentrations of proges-
terone in aortic cells from male humans. Decreases in cyclin
A and E messenger RNA were also documented, which
suggests interruption of the cell cycle at the G1/S transi-
tion. The identification of progesterone receptors in the
VSMCs from infragenicular origin as shown by our studies
implies a specific effect of the hormone on these cells.
Epidemiologic data suggest the relative risk of significant
coronary artery disease is lower in women administered
both estrogens and progestins as compared with those
prescribed estrogens alone.25 Our data further support that
progesterone may have an important role in this risk reduc-
tion, particularly in the diabetic setting where the risk of
atherosclerosis and its complications is higher.
In summary, we have shown a consistent antiprolifera-
tive effect of progesterone on VSMCs incubated in all
examined glucose and insulin levels. These data suggest
that progesterone possesses protective characteristics
against the accelerated atherosclerotic changes associated
with DM and IGT.
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